Drug Trial Radar · NCT07585760
CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment
Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
26
Planned (sponsor's estimate)
Start
Sep 10, 2026
Primary completion
May 1, 2028
Study completion Dec 30, 2028
Sponsor
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a single-center, single-arm, open-label, Phase II interventional clinical trial designed to evaluate the efficacy and safety of a CM336 and isatuximab regimen in patients with newly diagnosed multiple myeloma (NDMM) accompanied by renal impairment (\[eGFR\] \< 40 mL/min). Enrolled subjects will receive three consecutive cycles of induction therapy with CM336 in combination with isatuximab.
Conditions
- Multiple Myeloma (MM)
- Multiple Myeloma Light Chain Induced Renal Insufficiency
Interventions
CM336 Plus IsatuximabDrug
CM336: Administered subcutaneously (SC) via a step-up dosing regimen, which includes a step-up dosing phase and a target dosing phase. Upon reaching the target dose, it will be administered once weekly. Isatuximab: Administered intravenously (IV) at a dose of 10 mg/kg, given weekly during Cycle 1, and every two weeks during Cycles 2 and 3.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Renal Response Rate (Minor Response or better)Time frame: At the end of Cycle 3 (each cycle is 28 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
Tianjin, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.